| Literature DB >> 26005511 |
Gyrd O Gjevestad1, Kirsten B Holven2, Stine M Ulven3.
Abstract
Regular physical activity seems to be one of the most important contributors to prevent disease and promote health. Being physically active reduces the risk of developing chronic diseases such as cardiovascular disease, diabetes, and some types of cancers. The molecular mechanisms are however not fully elucidated. Depending on duration and intensity, exercise will cause disruption of muscle fibers triggering a temporary inflammatory response. This response may not only involve the muscle tissue, but also peripheral tissues such as white blood cells, which are important components of the immune system. The immune system plays a vital role in the development of atherosclerosis, thereby making white blood cells relevant to study when looking at molecular mechanisms induced by physical activity. In this review, we summarize the existing literature on exercise and gene expression in human white blood cells, and discuss these results in relation to inflammation and atherosclerosis.Entities:
Keywords: Atherosclerosis; Exercise; Gene expression; Inflammation; Leukocytes; Lymphocytes; Monocytes; PBMCs; Peripheral mononuclear blood cells; Physical activity
Year: 2015 PMID: 26005511 PMCID: PMC4439514 DOI: 10.1007/s12170-015-0463-4
Source DB: PubMed Journal: Curr Cardiovasc Risk Rep ISSN: 1932-9520
Common inflammatory markers, included in this review, and their biological functions relevant for atherosclerosis and physical activity
| Inflammatory markers | Gene symbol | Function |
|---|---|---|
| Chemokine (C-C motif) ligand 2 | CCL2 | Involved in chemotactic activity for monocytes and basophils, binding to CCR2 and CCR4. |
| Chemokine (C-C motif) ligand 3 | CCL3 | Involved in the acute inflammation by recruitment and activation of leukocytes. |
| Chemokine (C-C motif) ligand 4 | CCL4 | Involved in the migration of immune cells, a chemoattractant. |
| Chemokine (C-C motif) ligand 5 | CCL5 | Involved in recruiting leukocytes to inflammatory sites. |
| Chemokine (C-C motif) receptors (2, 3 and 4) | CCR2, 3, 4 | Involved in the regulation of cell trafficking, important in inflammation, binds to cytokines. |
| Chemokine (C-X-C motif) ligand 16 | CXCL16 | Involved in the migration of immune cells, a chemoattractant. |
| Endothelial nitric oxide synthase | NOS3 | Involved in the generation of NO in blood vessels, regulating vascular tone, and platelet aggregation. |
| GATA binding protein 3 | GATA3 | T cell-specific transcription factor involved in the regulation of T cell development. |
| Glutathione peroxidase | GPX | Involved in the detoxification of hydrogen peroxide. |
| Heat shock 27 kDa protein-associated protein 1 | HSPBAP1 | Involved in stress resistance; actin organization, and translocation from the cytoplasm to the nucleus. |
| Heat shock 70 kDa protein 1A | HSPA1A | Involved in stress resistance; stabilizing proteins against aggregation and mediates the folding of newly translated proteins. |
| Heat shock 70 kDa protein 6 | HSPA6 | Involved in stress resistance; protein folding, stabilization, and shuttling functions in response to stress. |
| Inducible nitric oxide synthase | NOS2 | Involved in immune response and important in cellular signaling, produces NO. |
| Interferon gamma | IFNG | Involved in the regulation of immune and inflammatory response, promotes Th1 differentiation. |
| Interleukin 1 receptor antagonist | IL1RN | Inhibits the activity of IL1A/IL1B, and modulates a variety of interleukin 1-related immune and inflammatory responses. |
| Interleukin 1 receptor-like 1 | IL1R1 | Involved in cytokine-induced immune and inflammatory response. |
| Interleukin 10 | IL10 | Downregulates the expression of Th1 cytokines, enhances B cell survival, proliferation, and antibody production, able to block NF-κB activity. |
| Interleukin 13 | IL13 | Immunoregulatory cytokine that plays a role in B cell maturation and differentiation, downregulates macrophage activity inhibiting the production of pro-inflammatory cytokines and chemokines. |
| Interleukin 1a, interleukin 1b | IL1A/IL1B | Proliferation and maturation of lymphocytes, involved in inflammation and acute-phase response. |
| Interleukin 4 | IL4 | Pleiotropic cytokine involved in T cell and macrophage differentiation and modulate the differentiation to Th2. |
| Interleukin 6 | IL6 | A pleiotropic cytokine that plays important roles in inflammation and the acute-phase response. |
| Interleukin 8 | IL8 | Involved in the acute inflammatory response, a chemoattractant. |
| Matrix metallopeptidase 9 | MMP9 | Involved in the breakdown of extracellular matrix and tissue remodeling. |
| NADPH oxidase | NADPH oxidase | Involved in the vascular superoxide production. |
| Prostaglandin-endoperoxide synthase 2 | PTGS2 | An enzyme responsible for formation of prostanoids, involved in inflammation. |
| Superoxide dismutase 1 | SOD1 | Involved in the anti-oxidative defense destroying free superoxide radicals in the body. |
| Superoxide dismutase 2 | SOD2 | Involved in the anti-oxidative defense destroying free superoxide radicals in the body. |
| TNF receptor-associated factor 6 | TRAF6 | Involved in signal transducing in NF-kappa B pathway. |
| Toll-like receptors 2, 4, and 7 | TLR2, 4, and 7 | Involved in recognition of pathogen-associated molecular patterns (PAMPs), mediate the production of cytokines necessary for the development of effective immunity. |
| Transforming growth factor beta | TGFB | Involved in proliferation, differentiation, adhesion, and migration. |
| Tumor necrosis factor alpha | TNF | Prototypical pro-inflammatory cytokine, plays a central role in inflammation, immune system development, and apoptosis. |
Fig. 1Flow chart showing the result of the combined literature search in Ovid Medline and EMBASE and the selection of papers
Gene expression studies performed in human white blood cells (lymphocytes, monocytes, and PBMCs) after exercise
| Study | Intervention | Description of exercise | Subjects (age, n, gender) | Genes investigated | Regulation after exercise (↑,↓, ↔) |
|---|---|---|---|---|---|
| (a) Gene expression studies performed in white blood cells after an acute bout of exercise | |||||
| Ullum et al. [ | Moderately trained subjects cycled for 1 h. Blood samples were drawn before exercise, during the last minute of exercise, and 2 and 4 h after exercise. For six subjects, blood samples were also drawn 1, 3, 5, and 6 h after exercise. | Ergometric bicycle exercise for 1 h at 75 % of VO2max. |
| IL6, IL1A, IL1B, TNF | IL1A, IL1B, IL6, and TNF ↔ |
| Natelson et al. [ | Walking on a treadmill until exhaustion. Blood samples were taken before exercise and 10 min into recovery. | Gradually increasing walking speed up to 6.4 km/h. Thereafter, the speed was held constant, but the incline was increased every min with 2 % grades. Subjects stopped walking at exhaustion (45.6 ± 0.8 min). |
| TNF, IL1A, IL1B, IL2, IL4, IL10, and IFNG | TNF ↓, IL1A, IL1B, IL2, IL4,IL10, and IFNG ↔ |
| Ostrowski et al. [ | Subjects participated in a marathon race. Blood samples were taken 1 week before, immediately after exercise, and 2 h into recovery of the marathon race. | Marathon race |
| IL6, IL1RN, IL1B, and TNF | IL1RN↑ in 5 PBMC samples. |
| Fehrenbach et al. [ | Two groups: trained athletes ( | Trained athletes (53.3 ± 18.4 km/week) performed a half-marathon. Untrained subjects were sitting in the laboratory. |
| HSPBAP1, HSPA6 | HSPBAP1 and HSPA6↑ in athletes, returned to baseline after 24 h in athletes. |
| Moldoveanu et al. [ | Untrained subjects exercising 3 h at 60–65 % VO2max. Blood samples were taken at baseline and 30, 60, 120, 180, 210, 240, and 300 min after baseline. Subjects came in for a final blood sample 24 h after baseline. | 1 h cycling, 1 h inclined treadmill, and 1 h cycling without pause or recuperation. |
| IL6, IL1B, and TNF | IL6, IL1B, and TNF ↔ |
| Niess et al. [ | Well-trained athletes (55.7 ± 5.5 km/week) and untrained subjects (<3 h recreational activity/week) were included. The athletes (TG) ran a half-marathon, while the untrained group (CG) performed an exercise test on a treadmill. Blood samples were collected before exercise; immediately after; 3, 24, and 48 h into recovery. | Half-marathon and graded exercise test. Graded exercise test on a treadmill—speed was increased with 2 km/h every third minute until exhaustion. The incline was kept constant at 1 %. After 15 min rest, a continuous ran was performed at 110 % of the anaerobic threshold until exhaustion. | n TG = 10 | NOS2 | NOS2 ↑ directly after the half-marathon (peak after 3 h). |
| Thompson et al. [ | Habitually active (5 ± 1 h per week) subjects performed an exercise and a rest trial (sitting calmly in the lab). Blood samples were collected before, immediately after exercise, and 1 and 2 h into recovery. A final blood sample was collected the following day. | 75 min of running on a treadmill at 70 % VO2max. |
| HO-1 | HO-1↑, the peak varied in time among the individuals. |
| Ferrer et al. [ | Swimmers on an amateur team participated in a 1 h swimming session. | A series of intermitted 50 m swim of progressively increasing speed for 30 min, with a 10–15 s rest between swims. The next half hour, the swimmers continued swimming 50 m, with 10–15 s rest, at 75–80 % of VO2max. |
| Catalase, GPX, BCL2, PPARGC1A, and UCP-3 | BCL2, UCP-3 ↓ for both genders, catalase, GPX, PPARGC1A, ↔ in both genders. |
| Sakharov et al. [ | Trained skiers performed a treadmill test; 15 ± 0.5 min. Blood samples were taken before and immediately after exercise. | Step-by-step increasing power treadmill test; initial treadmill velocity 3.0 m/s, slope angle 1°, velocity increment 0.5 m/s. |
| HSPA1A | HSPA1A↑ |
| Sureda et al. [ | Soccer players played a training match. Blood samples were taken before and after the match. | 60-min soccer game with different intensities (low 70–80 %, medium 80–90 %, and high 90–100 %). |
| HO-1 | HO-1↑ in moderate and high intensity groups. |
| Jenkins et al. [ | Endurance-trained athletes ( | 30-min treadmill running at 75 % VO2max. |
| NOS3, SOD, SOD1, SOD2, GPX1, CD34, and VEGF | In CD34+ cells: SOD1↓ in sedentary group after exercise. NCF1 and NOX2↓ in both groups. |
| Li et al. [ | Healthy tai chi (TC) players performed a Yang style TC. Blood samples were collected before and immediately after the exercise. | 1 h Yang style TC consisting average 5 min warm-up, TC for 45 min, and 5 min cooldown. |
| IL13 | IL13↑ |
| Nickel et al. [ | Three age-matched groups depending upon exercise level; lean elite ( | Marathon race |
| TLR2, TLR4, TLR7 | Right after the marathon: |
| Thomas et al. [ | Untrained subjects were recruited to an acute bout of exercise. Blood samples were collected before; immediately after exercise; and 1.5, 3, and 24 h into recovery. | 45-min cycling at 70 % of VO2max. |
| PPARG, CD36, NR1H3, ABCA1, PPARGC1A, CETP, L-CAT, APOA1 | CD36, NR1H3, ABCA1↑ |
| Bernecker et al. [ | Participants participated in a marathon race. Blood samples taken directly before and within 1 h after finishing the race. | Marathon race |
| TNF, IL6 | TNF, IL6 ↔ |
| Ulven et al. [ | Well-trained subjects performed a 1-h cycling. Blood samples were drawn before and after exercise. The exercise test day was repeated twice. | One-hour ergometer cycling at 70 % of VO2max. |
| 18 genes | IL1B, CXCL16, IL8, PTGS2, TBX21, and GATA3↑ |
| Xiang et al. [ | Trained subjects were randomly recruited from a lager cohort to run a marathon race. Average training mileage before the race was 17.4 ± 9.1 miles/week. Blood samples were collected 24–48 h before and 1 week after completing the race. | Marathon race |
| 84 genes | IL4, GATA3, CCR4, CCR3, IRF1, CCR2, CEBPB, GPR44, NFATC2, NFATC2IP, TMED1, LAG3, LAT, MAP2K7, CD28, CD8 ↑ |
| Connolly et al. [ | Healthy subjects were included to perform a cycle ergometric. Blood samples taken before exercise, end of exercise, and 60 min into recovery. | 30-min constant-work-rate ergometric cycling (80 % peak VO2max) |
| Whole genome | 311 genes diff reg. between pre- and end-ex, such as HSPA1A, HSPA1B, CCL3, CCL4, CLL5, NR4A2 and RGS1↑, IL1RN, and CD14 ↔ |
| Buttner et al. [ | Subjects already participating in leisure activities (6.0 ± 2.6 h/week) performed a strenuous treadmill exercise. Two weeks after they performed a moderate treadmill exercise. Blood samples were taken before and 1 h after exercise. | One bout of strenuous treadmill exercise (80 % of VO2max until exhaustion—mean time 39.0 ± 14.8 min) and one bout of moderate treadmill exercise (60 % of VO2max), identical time periods. |
| Whole genome | 39 genes↑, among these HSPA1A, MMP9, IL8RA, IL1 receptor, SLC2A3, and IL1R2, |
| Radom-Aizik et al. [ | Early- and late puberty girls (not involved in competitive sports) performed ergometric cycling. Blood were obtained at rest and after exercise. | Ten 2-min bouts of constant-work-rate ergometric cycling with 1-min rest between each interval. The work rate was individualized to 50 % of VO2max. |
| Whole genome | Late puberty; 611 genes ↑, 266 genes ↓ |
| Radom-Aizik et al. [ | Early- and late puberty boys (not involved in competitive sports) performed ergometric cycling. Blood were obtained at rest and after exercise. | Ten 2-min bouts of constant-work-rate ergometric cycling with 1 min rest between each interval. The work rate was individualized to 50 % of VO2max. |
| Whole genome | Late puberty; 517 genes (CCL4, FASLG, GZMA, PRF1, and HAPA1B) ↑ and 729 genes (IL8)↓ |
| Carlson et al. [ | Trained subjects with weight lifting experience performed an acute bout of resistance exercise—30 min following a 12-h fast. Blood samples were taken at rest (baseline), immediately after exercise (post-ex), and 2 h into recovery. | Six sets of parallel back squat followed by six sets of seated leg press. Each exercise consisted of two warm-up sets of 10 repetitions at 45 and 55 % of 1 RM and four sets of 10 repetitions of 65 % of 1 RM. 2-min resting period between sets were allowed. |
| Whole genome | From baseline to post-ex (six genes); NR4A2, CREM, EREG, AREG, DUSP2, and RGS1 ↑. |
| Kimsa et al. [ | Ergometric cycling looking at the expression pattern of TGFB-signaling pathways. Blood samples were drawn before exercise (pre-ex), immediately after exercise (post-ex), and 15 min into recovery. | Unloaded cycling for 5 min, intensity increased by 40 W every 3 min up to maximal exercise intensity and 60–70 rpm was maintained. |
| Whole genome | Pre-ex to post-ex: RUNX3, TGFBR3, and MLC1↑ |
| Maltseva et al. [ | Skiers engaged in regular training for the last 5 years were included for a treadmill run. Blood samples were taken before, directly after exercise, and 30 and 60 min into recovery. | Treadmill running for 30 min at 80 % of VO2max. |
| Whole genome | HSPAIA↑ after exercise, stabilized during recovery. |
| Sakharov et al. [ | Highly trained skiers participated in a treadmill test (RTE). Two weeks later, seven of these performed a moderate treadmill test (MT) for 30 min. Blood samples were taken before and immediately after both tests. | The initial treadmill test (RTE) was performed until exhaustion with an incremental step protocol. The second treadmill test (MT) was performed at moderate intensity at 80 % VO2max for 30 min. | n (RTE) = 19 | Whole genome | 310 genes ↑ after RTE. |
| Kimsa et al. [ | Ergometric cycling and expression pattern of inflammation-related genes. Blood samples were drawn before exercise (pre-ex), immediately after exercise (post-ex), and 15 min into recovery. | Unloaded cycling for 5 min, intensity increased by 40 W every 3 min up to maximal exercise intensity and 60–70 rpm was maintained. |
| Whole genome | Pre-ex to post-ex: IL2RB, IL18R1, TXLNA↑, IL5RA, IL6 ↓ |
| Radom-Aizik et al. [ | Participants performed an intermittent-exercise protocol. Blood samples were taken 30 min before exercise (baseline) and immediately after exercise. | Ten 2-min bouts of constant-work-rate ergometric cycling with 1 min rest between each interval. The work rate was individualized to 82 % VO2max. |
| Whole genome | The exercise protocol altered the expression level of 894 annotated genes in the circulating monocytes, such as EREG, CXCR4↑, TNF, TLR4, and CD36↓ |
| Storey et al. [ | Competitive weight lifters performed a standardized weightlifting program after a period with either intensified or reduced training programs. Blood samples were collected before training, right after exercise, and 3 h into recovery. | Six to eight sets of one to three repetitions of power snatch, power clean, and back squat. Two final sets at 90 % of max. Duration of acute bout, 90 min. |
| Whole genome and CCL4, CXCR4, and DDIT4 | 202 regulated genes associated with cell-to-cell signaling and immune cell trafficking, organismal survival, inflammation and cell cycle, and cell death. |
| (b) Gene expression studies performed in white blood cells after prolonged exercise. | |||||
| Jimenez-Jimenes et al. [ | Two bouts of exercise before and after 8 weeks of leg press eccentric training. Training was performed twice a week. Blood samples were taken at rest (baseline), immediately after exercise, and 3 h into recovery. | Eccentric bouts: 10 sets of 10 repetitions. 3-min rest between sets. 60 % of MIVC. |
| NOS2, PTGS2, IL6 | Following the first bout and maintained after 3 h: NOS2, PTGS2, and IL6 mRNA↑. NF-κB activation↑. |
| Yakeu et al. [ | Sedentary subjects—8 weeks low-intensity training program. | Walking 10,000 steps/day on a treadmill (within 75 min), three times a week. |
| CCL2, IL6, IL4, IL10, TNF, MR, CD14, AMAC1, CXCL2, PPARGC1A, PPARGC1B, PPARA, and PPARG/D | PPARGC1A, PPARGC1B, IL4, CD14, and MR↑ |
| Gano et al. [ | Walking every day for 2 months. Blood samples taken before and after the intervention period. | 40–45 min at 70–75 % VO2max. |
| AGER, NCF1, CCL2, NOS2, NF-κB, TNF, and IL6 | AGER, NCF1, and CCL2 ↓ |
| Fernandez-Gonzalo et al. [ | Sedentary people were divided into a training group (TG) and a control group (CG). Both groups performed two acute bouts of exercise, before and after a 6-week eccentric training program. Blood samples were taken before exercise, immediately after, and 2 h into recovery. | Acute bout: 12 sets of 10 repetitions, 60 % of the MVIC, 3-min rest between each set, on a barbell squat. | n TG = 12 | CD14, TLR4, and TNF | First bout of exercise in both groups: CD14, TLR4, and TNF↑ (no diff between groups). |
| Fernandez-Gonzalo et al. [ | Sedentary people were divided into a training group (TG) and a control group (CG). Both groups performed two acute bouts of exercise, before and after a 6-week eccentric training program. Blood samples were taken before exercise, immediately after, and 2 h into recovery. | Acute bout: 12 sets of 10 repetitions, 60 % of the MVIC, 3-min rest between each set, on a barbell squat. | n TG = 12 | CD14, TLR4, and TRAF6 | First bout of exercise in both groups: CD14, TLR4, and TRAF↑ |
| Rodriguez-Miguelez et al. [ | Two groups; training group (TG) and control group (CG). Resistance training for 8 weeks two times per week, no changes in daily routines for CG. Blood samples were collected before and after the exercise period. | 10 min warm-up at a cycle ergometer, three different exercises: leg press, biceps curl, and pec deck. Number of sets 3 × 8, 3 × 10, and 3 × 12 at 60 % of 1 RM during weeks 1–3. 3 × 8, 3 × 10, and 3 × 12 at 70 % of 1 RM during weeks 4–6. 3 × 8, 3 × 10 at 80 % of 1 RM during weeks 7 and 8. | n TG =16 | IL10, TNF | IL10 ↑ in the TG. |
| Tringali et al. [ | Two groups: elite gymnastics and artistic gymnasts (recreational level). mRNA measured at rest in spring and fall. | Elite gymnasts performed 3-h daily training, 18 ± 4 h training a week. |
| IL6, IL10, TNF, and IFNG | Elite gymnasts vs. recreational gymnasts; IL6 and TNF ↑in elite gymnasts, IL10 and IFNG ↔ |
| Thompson et al. [ | 24 weeks of training followed by 2 weeks of detraining (removal of exercise). Samples from six individuals with high basal plasma IL6 levels were collected at baseline, at end of exercise, and after 2 weeks of detraining. | Training 3–4 times a week, 30–60 min each time, starting at 50 % of VO2max increasing steadily to 70 % of VO2max. |
| Whole genome | 31 probes returned to baseline after 2 weeks of detraining. 22 probes at the same levels as after 2 weeks of detraining (compared to end of the 24-week training program). |
| Dias et al. [ | Healthy untrained subjects were included to 18 weeks of running three times a week. | 80-min session including 5 min warm-up, 60 min run, and 15 min cooldown activities. The intensity corresponded to the anaerobic threshold and respiratory compensation point. |
| Whole genome | 152 transcripts↑, 59 transcripts ↓ |
Studies performed using an acute bout of exercise mostly used PBMCs except for the study of Buttner el al, Fehrenbach et al., Maltseva et al., Nieman et al., Niess et al., Sakharov et al. (two studies) were leukocytes were used and the study of Ferrer et al. and Thompson et al. were lymphocytes were used. In eight out of the nine studies performed using prolonged exercise as the intervention, PBMCs were used. Yakeu et al., 2010 used leukocytes. ↑ indicates genes being upregulated, ↓ indicates genes being downregulated, and ↔ indicates no changes in genes expression after exercise
MIVC maximal isometric voluntary contraction, VO max maximal oxygen uptake, yrs years, h hours, IL interleukin, IL1B interleukin 1 beta, TNF tumor necrosis factor-α, IFNG interferon gamma, IL1RN interleukin-1 receptor antagonist, HSP heat shock protein, NOS2 inducible nitric oxide synthase 2, mRNA messenger ribonucleic acid, HO-1 heme oxygenase 1, GPX glutathione peroxidase, BCL2 B cell lymphoma 2, UCP-3 mitochondrial uncoupling protein 3, HSPA6 heat shock protein 70 kDa protein 6, HSPBAP1 heat shock protein 27 kDa-associated protein 1, HSPA1A heat shock 70 kDa protein 1, NOS3 endothelial nitric oxide synthase, SOD superoxide dismutase, CD cluster of differentiation, TLR toll-like receptor, PPARG peroxisome proliferator-activated receptor gamma, NR1H3 nuclear receptor family 1 group H member 3, ABCA1 ATP-binding cassette transporter 1, CEPT cholesteryl ester transfer protein, L-CAT phosphatidylcholine-sterol acyltransferase, ApoA1 apolipoprotein A-I, CXCL chemokine (C-X-C motif) ligand, PTGS2 prostaglandin-endoperoxidase synthase 2, TBX21 T-box transcription factor 21, GATA3 trans-acting T cell-specific transcription factor, TGFB transforming growth factor-β, FOXP3 forkhead box P3, CCR C-C chemokine receptor, IRF1 interferon regulatory factor 1, CEBPB CCAAT/enhancer-binding protein beta, GPR44 G protein-coupled receptor 44, NFATC2 nuclear factor of activated T cells cytoplasmic 2, NFATC2IP nuclear factor of activated T cells cytoplasmic 2-interacting protein, TMED1 transmembrane emp24 domain-containing protein 1, LAG3 lymphocyte-activation gene 3, LAT linker for activation of T cells, MAP2K7 mitogen-activated protein kinase kinase 7, TBX21 T cell-specific T-box transcription factor T-bet, Th T helper cell, NR4A2 nuclear receptor subfamily 4 group A member 2, RGS1 regulator of G protein signaling 1, MMP9 matrix metallopeptidase 9, SLC2A3 solute carrier family 2 (facilitated glucose transporter) member 3, YES Yamaguchi sarcoma viral oncogene homologue, FASLG fas ligand (TNF superfamily, member 6), GZMA granzyme A (granzyme 1, cytotoxic T lymphocyte-associated serine esterase 3), PRF1 perforin-1, CREM cAMP responsive element modulator, EREG epiregulin, AREG amphiregulin, DUSP2 dual specificity phosphatase 2, DAAM1 disheveled-associated activator of morphogenesis 1, ORM1 orosomucoid 1, ARG1 arginase 1, PDGFD platelet-derived growth factor D, SIK1 salt-inducible kinase 1, TPST1 tyrosylprotein sulfotransferase 1, LAIR2 leukocyte-associated immunoglobulin-like receptor 2, RUNX3 runt-related transcription factor 3, TGFBR3 transforming growth factor beta receptor III, MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1, GRB2 growth factor receptor-bound protein 2, rpm revolutions per minute, PGLYRP1 peptidoglycan recognition protein 1, TXLNA taxilin alpha, CSF2 colony stimulating factor 2, CXCR chemokine (C-X-C motif) receptor, DDIT4 DNA-damage-inducible transcript 4, NF-κB nuclear factor-kappa B, MCP-1 monocyte chemoattractant protein-1, MR mannose receptor, AMAC-1 alternative macrophage activation-associated C-C chemokine-1, PPARGC1A peroxisome proliferator-activated receptor gamma coactivator 1 alpha, PPARGC1B peroxisome proliferator-activated receptor gamma coactivator 1 beta, PPARG/PPARD peroxisome proliferator-activated receptor gamma or delta, AGER receptor for advanced glycosylation end product-specific receptor, NCF1 nicotinamide adenine dinucleotide phosphate-oxidase subunit p47phox, NOX2 NADPH oxidase 1 subunit gp91 phox, TRAF6 TNF receptor-associated factor 6, CLC Charcot-Leyden crystal galectin, PARD6G par-6 family cell polarity regulator gamma, INSL6 insulin-like 6, RET ret proto-oncogene, CPA2 carboxypeptidase A2, CPS1 carbamoyl-phosphate synthase 1, SGOL1 shugoshin-like 1